Wikisage, the free encyclopedia of the second generation, is digital heritage
Eslicarbazepine: Difference between revisions
Jump to navigation
Jump to search
m (sup) |
|||
| Line 11: | Line 11: | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action] | ||
==References== | |||
<references/> | <references/> | ||
Revision as of 03:24, 20 September 2015
S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]
Pharmacy and chemistry
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]
Pharmacology
References
- ↑ Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
- ↑ Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
- ↑ A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
- ↑ https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT